is this you? Claim your profile.
is this you? Claim your profile.
Senior Vice President, Global Regulatory Affairs and Clinical Safety
HQ Phone:  (908) 740-4000
Direct Phone: (650) ***-****
+ Get 10 Free Contacts a Month
It's free and takes 30 seconds
2000 Galloping Hill Road
Kenilworth, New Jersey,07033
For over a century, Merck has been a global health care leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and animal health products, we work ... more.
Vice President, Global Regulatory Affairs, Therapeutic Area Head for Inflammation, Infectious Disease and Ophthalmology
Global Regulatory Therapeutic Area Head
Drug Information Association
The Food and Drug Law Institute
Member of the Strategic Planning Committee and the FDLI Drugs and Biologic Committee
Biologics Industry Representative of the Risk Communication Advisory Committee
National Committee for Clinical Laboratory Standards
The George Washington University School of Medicine
Sandra A. Milligan, JD, MD
DIA | Biography Sandra A. Milligan, JD, MD Sandra A. Milligan, MD, JD, currently serves as Senior Vice President and Head of Global Regulatory Affairs and Clinical Safety of Merck, consisting of the global Regulatory, Safety and CMC functions of Merck Research Laboratories. She previously served as Vice President, Global Regulatory, Immunology, Respiratory, Infectious Diseases and Ophthalmology for Genentech/Roche where she developed and directed global strategic regulatory plans to facilitate and optimize product development, regulatory approval, and commercialization. Previous to Genentech/Roche she served at Amgen for almost 10 years in various roles, including Global Regulatory Therapeutic Area Head for the Bone franchise, as Head of Regulatory Communications Strategy & Operations, and as Senior Counsel for the Development, Regulatory & Compliance Law Group, where she provided strategy for development, regulatory and safety groups. In addition to serving on the DIA Board of Directors and current President-Elect, Sandra has served as the Program Chair for the DIA 2013 Annual Meeting in Boston, as well as co-chair of the Public Policy/Health Care Compliance/Regulatory Law Annual Meeting track. Sandra is a graduate of The George Washington University School of Medicine and the Georgetown University Law Center and attended UC Irvine for undergraduate studies.
â€œTruthful, competent, and reliable evidence should be a part of the dialogue with healthcare decision-makers,â€� said Dr. Sandra Milligan, SVP of global regulatory affairs and clinical safety at Merck, during an FDA hearing in November.
DIA Global Chief Executive Barbara Lopez Kunz and Dr. Sandra Milligan, DIA President and Chairman of the Board, reflect on how DIA breaks through the barriers between academia, industry, regulatory and government agencies, and patient groups, to fulfill the noble promise of our respective professions: To deliver safe and effective health care products to patients all around the world.
Sandra A. Milligan,MD, JD Sandra A. Milligan, Sandra A. Milligan,MD, JD Sandra A. Milligan, Sandra A. Milligan,MD, JD Sandra A. Milligan,
Sandra A. Milligan,MD, JD
Sandra A. Milligan, Sandra A. Milligan,MD, JD Sandra A. Milligan, Sandra A. Milligan,MD, JD Sandra A. Milligan,
"As a valued member of our LaunchPoint ecosystem, we're thrilled to have EverString join the launch of Marketo ABM," said Robin Ritenour, senior vice president of business development at Marketo, in a statement.